AMD

Izervay

Pharma

FDA signs off on Astellas' recently acquired GA drug Izervay

After Astellas’ $5.9B buyout of eye disease specialist Iveric Bio, the FDA has signed off on the main asset acquired in the deal.

Kevin Dunleavy Aug 7, 2023 11:16am

Regeneron

FDA grants priority review to Regeneron's high-dose Eylea filing

Feb 23, 2023 10:05am

eyeball retinal diseases

Bausch + Lomb kicks off 'What Sight Inspires You' campaign

Feb 13, 2023 7:15am